Pamela J Burgess

Array ( [id] => 18656235 [patent_doc_number] => 20230302121 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-28 [patent_title] => Anti COVID-19 Therapies targeting nucleocapsid and spike proteins [patent_app_type] => utility [patent_app_number] => 18/312532 [patent_app_country] => US [patent_app_date] => 2023-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8897 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18312532 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18612350 [patent_doc_number] => 20230279082 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => Broadly-Neutralizing HIV Antibodies [patent_app_type] => utility [patent_app_number] => 18/297301 [patent_app_country] => US [patent_app_date] => 2023-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30794 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18297301 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18673104 [patent_doc_number] => 20230310579 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => RECOMBINANT VIRUS LIKE PARTICLES USING BOVINE IMMUNODEFICIENCY VIRUS GAG PROTEIN [patent_app_type] => utility [patent_app_number] => 18/153667 [patent_app_country] => US [patent_app_date] => 2023-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20445 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18153667 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18389916 [patent_doc_number] => 20230158134 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-25 [patent_title] => CHIMPANZEE ADENOVIRUS CONSTRUCTS WITH LYSSAVIRUS ANTIGENS [patent_app_type] => utility [patent_app_number] => 18/075064 [patent_app_country] => US [patent_app_date] => 2022-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22320 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 251 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18075064 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19354109 [patent_doc_number] => 12054538 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-08-06 [patent_title] => Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120 [patent_app_type] => utility [patent_app_number] => 18/046481 [patent_app_country] => US [patent_app_date] => 2022-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 34 [patent_no_of_words] => 13739 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 221 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18046481 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18449636 [patent_doc_number] => 20230190912 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => Zika Vaccines and Methods of Use [patent_app_type] => utility [patent_app_number] => 18/045330 [patent_app_country] => US [patent_app_date] => 2022-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7939 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18045330 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18675705 [patent_doc_number] => 20230313327 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => Compositions and Methods for Determining Resistance to Inhibitors of Virus Enter Using Recombinant Virus Assays [patent_app_type] => utility [patent_app_number] => 17/959168 [patent_app_country] => US [patent_app_date] => 2022-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17881 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17959168 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18565761 [patent_doc_number] => 20230256088 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-17 [patent_title] => IMMUNO-ONCOLOGY COMPOSITIONS AND METHODS FOR USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/950989 [patent_app_country] => US [patent_app_date] => 2022-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20171 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17950989 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18449634 [patent_doc_number] => 20230190910 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => SCAFFOLDED HIV-1 VACCINE IMMUNOGENS [patent_app_type] => utility [patent_app_number] => 17/896799 [patent_app_country] => US [patent_app_date] => 2022-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15773 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17896799 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18196875 [patent_doc_number] => 20230050394 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-16 [patent_title] => METHOD AND COMPOSITION FOR DETERMINING SPECIFIC ANTIBODY RESPONSES TO SPECIES OF FILOVIRUS [patent_app_type] => utility [patent_app_number] => 17/883189 [patent_app_country] => US [patent_app_date] => 2022-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17858 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17883189 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18451528 [patent_doc_number] => 20230192806 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => ENGINEERED IMMUNE-MOBILIZING T-CELL RECEPTORS WITH ENHANCED AFFINITY FOR HIV-1 GAG [patent_app_type] => utility [patent_app_number] => 17/817301 [patent_app_country] => US [patent_app_date] => 2022-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10737 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17817301 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18141064 [patent_doc_number] => 20230014906 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-19 [patent_title] => FC-FUSION PROTEIN DERIVATIVES WITH HIGH DUAL HIV ANTIVIRAL AND IMMUNOMODULATORY ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/816708 [patent_app_country] => US [patent_app_date] => 2022-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23160 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17816708 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18451978 [patent_doc_number] => 20230193257 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => TAT-INDUCED CRISPR/ENDONUCLEASE-BASED GENE EDITING [patent_app_type] => utility [patent_app_number] => 17/866261 [patent_app_country] => US [patent_app_date] => 2022-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20827 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17866261 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17981250 [patent_doc_number] => 20220347286 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => INACTIVATED VACCINE FOR CHIKUNGUNYA VIRUS [patent_app_type] => utility [patent_app_number] => 17/851813 [patent_app_country] => US [patent_app_date] => 2022-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6226 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17851813 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18158447 [patent_doc_number] => 20230025038 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-26 [patent_title] => VIRUS LIKE PARTICLE COMPOSITIONS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/850706 [patent_app_country] => US [patent_app_date] => 2022-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22123 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17850706 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18511360 [patent_doc_number] => 20230227505 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-20 [patent_title] => IDENTIFICATION AND APPLICATION OF ALV-J MHC-B2 RESTRICTIVE EPITOPE PEPTIDE [patent_app_type] => utility [patent_app_number] => 17/831388 [patent_app_country] => US [patent_app_date] => 2022-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6698 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17831388 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18762946 [patent_doc_number] => 11813325 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-14 [patent_title] => Expression systems comprising nucleic acids encoding HIV-1 protease cleavage site polypeptides [patent_app_type] => utility [patent_app_number] => 17/830652 [patent_app_country] => US [patent_app_date] => 2022-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 14 [patent_no_of_words] => 8019 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17830652 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17897067 [patent_doc_number] => 20220306729 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-29 [patent_title] => NEUTRALIZING ANTIBODIES THAT BIND TO THE ZIKA VIRUS DOMAIN III ENVELOPE REGION [patent_app_type] => utility [patent_app_number] => 17/749044 [patent_app_country] => US [patent_app_date] => 2022-05-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35705 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17749044 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19258010 [patent_doc_number] => 12018053 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-25 [patent_title] => Method for detecting flavivirus-specific antibodies utilizing flaviviral NS1 polypeptides comprising the wing domain [patent_app_type] => utility [patent_app_number] => 17/705704 [patent_app_country] => US [patent_app_date] => 2022-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14580 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 153 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17705704 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18117538 [patent_doc_number] => 11548919 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2023-01-10 [patent_title] => SARS-CoV-2 polypeptide inhibitors directed against the Env TM domain and methods of treatment using said inhibitors [patent_app_type] => utility [patent_app_number] => 17/696104 [patent_app_country] => US [patent_app_date] => 2022-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 14 [patent_no_of_words] => 7914 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17696104 [rel_patent_id] =>[rel_patent_doc_number] =>)